Study shows mRNA-based COVID-19 antibody provides long-term protection in mice

2022-03-03 08:13:47Xinhua Editor : Li Yan ECNS App Download
Special: Battle Against Novel Coronavirus

Chinese researchers have developed an mRNA antibody that provided long-term protection against SARS-CoV-2 in animal tests, representing a promising antibody-based therapy for COVID-19 patients.

The study, published online in the international journal Cell Research, showed that a neutralizing human monoclonal antibody, called mRNA-HB27-LNP, provided effective protection against SARS-CoV-2 infection in mice for up to 63 days after administration.

Researchers from the Academy of Military Medical Sciences and Suzhou Abogen Biosciences Co., Ltd. made the antibody on a well-established mRNA-technology platform.

They tested the protective effect of the antibody with different doses and found that all animals that received either 1 mg/kg or 0.2 mg/kg of mRNA-HB27-LNP survived without any clinical symptoms. Treatment with 0.04 mg/kg of the antibody also achieved an 80 percent survival rate, and only minimal or very mild inflammation was observed.

The mRNA-HB27-LNP treatment also offered complete protection against the SARS-CoV-2 Beta variant in animal models in the study.

In addition, the mRNA technology-based antibody protected 50 percent of mice from SARS-CoV-2 even 63 days after administration, conferring much longer protection compared with traditional protein antibodies.

These results with mRNA-HB27-LNP support further clinical development for its potential application in preventing COVID-19, according to the study.


Most popular in 24h

MoreTop news


Back to top About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2022 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[京公网安备 11010202009201号] [京ICP备05004340号-1]